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Introduction: The aim of this study was to determine the prevalence of gastrointestinal and behavioural symptoms
occurring before (anticipatory/associative) and after methotrexate (MTX) administration, termed MTX intolerance, in
rheumatoid (RA) and psoriatic arthritis (PsA).
Methods: Methotrexate Intolerance Severity Score (MISS), previously validated in juvenile idiopathic arthritis
patients, was used to determine MTX intolerance prevalence in 291 RA/PsA patients. The MISS consisted of four
domains: abdominal pain, nausea, vomiting and behavioural symptoms, occurring upon, prior to (anticipatory) and
when thinking of MTX (associative). MTX intolerance was defined as ≥6 on the MISS with ≥1 point on anticipatory
and/or associative and/or behavioural items.
Results: A total of 123 patients (42.3%) experienced at least one gastrointestinal adverse effect. The prevalence of
MTX intolerance was 11%. MTX intolerance prevalence was higher in patients on parenteral (20.6%) than on oral
MTX (6.2%) (p < 0.001).
Conclusion: Besides well-known gastrointestinal symptoms after MTX, RA and PsA patients experienced these
symptoms also before MTX intake. RA and PsA patients on MTX should be closely monitored with the MISS for early
detection of MTX intolerance, in order to intervene timely and avoid discontinuation of an effective treatment.Introduction
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are
inflammatory disorders characterized by chronic arthritis
[1,2]. In RA and PsA treatment, methotrexate (MTX) is
the first-choice disease-modifying anti-rheumatic drug
(DMARD) due to low costs, efficacy and an acceptable
safety profile [3,4]. Serious adverse effects such as pulmon-
ary toxicity, hepatotoxicity and bone marrow suppression
are rare or transient if MTX is stopped [5]. In contrast,
gastrointestinal adverse effects are common, affecting as
many as 66% of patients [2,6-11]. Due to these adverse ef-
fects, up to 12% of RA and PsA patients discontinue MTX
after 6 months to 2 years of treatment [6-8,12].
Previously, we showed in juvenile idiopathic arthritis
(JIA) that 50.5% of patients suffered not only from a
myriad of gastrointestinal adverse effects after MTX in-
take, but also from adverse effects before MTX intake* Correspondence: m.bulatovic@umcutrecht.nl
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distribution, and reproduction in any medium(anticipatory) and when thinking of MTX (associative)
[13]. The latter symptoms arise as a classical condition-
ing response to gastrointestinal symptoms after MTX
administration. Therefore, the nature of MTX-induced
gastrointestinal adverse effects, which we termed MTX
intolerance, is complex, and could even further impede
the use of an otherwise effective drug. Although MTX-
induced gastrointestinal adverse effects occur frequently
in RA and PsA, severity and the type - in particular the
occurrence of anticipatory and associative symptoms -
have not been assessed.
The aim of this study was to determine the type and
prevalence of MTX-induced gastrointestinal adverse effects,
with a standardized questionnaire, in a large cohort of RA
and PsA patients.
Methods
Study design and patients
A cross-sectional descriptive study (ISRCTN13524271) in-
cluded RA and PsA patients attending the outpatient
wards of four general hospitals between May 2011 andd Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Baseline characteristics of 291 patients at the
time of completing the MISS
Characteristic Value in patient sample
Sex, female 181 (62.2)
Age, mean +/− SD years 59.4 +/− 12.4
Diagnosis
Rheumatoid arthritis 249 (85.6)
Psoriatic arthritis 42 (14.4)
Disease activity
Disease activity score 28, median (IQR)a 2.5 (1.7 to 3.2)
Physician’s global assessment,
median (IQR), (0 to 10 scale)b
2.0 (1.0 to 3.0)
Erythrocyte sedimentation
rate (mm/hour)
11.0 (5.0 to 22.0)
MTX use
Route of administration, oral 194 (66.7)
Dose, mg/week, median (IQR) 20.0 (12.5 to 25.0)
Other medication
NSAIDs 145 (49.9)
Proton-pump inhibitors 127 (43.6)
Anti-emetics 5 (1.7)
Oral steroids 31 (10.7)
Other DMARDsc 72 (24.7)
Characteristics are as calculated at the time of completing the MISS except
where indicated otherwise. Values are number (%), except where indicated
otherwise. aDisease activity score 28 was determined in 266 patients (274
rheumatoid arthritis and 19 psoriatic arthritis patients); bphysician’s global
assessment was determined in 268 patients; cof 72 patients on other DMARDs,
26 were on DMARDs (plaquenil, n = 24; leflunomide, n = 2) and 46 were on
biologic agents (infliximab, n = 24; adalimumab, n = 10; etanercept, n = 9;
abatecept, n = 2; golimumab, n = 1). MISS, methotrexate intolerance severity
score; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs;
DMARDs, disease-modifying anti-rheumatic drugs.
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3 months and received weekly folic acid (5 to 15 mg) [5].
Patients’ data on disease activity, MTX dose and route of
administration, co-medication, history of peptic ulcers and
smoking was collected. The study was approved by the
medical ethics committees of the University Medical Center
Utrecht and the four general hospitals in ‘s-Hertogenbosch,
Woerden, Amersfoort and Apeldoorn where the patients
were included. As the study burden for patients was low
and required no treatment changes, the ethics committees
waived the need for informed consent.
MTX intolerance severity score
To determine the prevalence of MTX-induced gastrointes-
tinal adverse effects, patients completed the methotrexate
intolerance severity score (MISS), previously developed
and validated in JIA [13]. The MISS consists of four do-
mains: abdominal pain, nausea, vomiting and behavioural
symptoms, assessing symptoms after MTX administration,
anticipatory (before MTX) and associative symptoms
(when thinking of MTX). The behavioural symptoms do-
main includes restlessness, irritability and refusal of MTX,
which develop in response to MTX-induced gastro-
intestinal symptoms and anticipation thereof. A patient
could score 0 (no symptoms), 1 (mild symptoms), 2
(moderate symptoms) or 3 (severe symptoms) points on
each item. MTX intolerance was defined as ≥6 points,
including at least one anticipatory, associative or behav-
ioural symptom [13].
MTX intolerance prevalence
The prevalence was determined of: a) individual symptoms
in all patients; b) MTX intolerance, defined as above; c) in-
dividual symptoms in MTX intolerant versus tolerant pa-
tients. MTX intolerance prevalence was compared between
patients on oral and parenteral MTX (chi-square test).
MTX intolerance severity, age, MTX dose, disease activity
parameters and medication use were compared in tolerant
versus intolerant patients, and in intolerant patients on oral
versus parenteral MTX (t-test, Mann–Whitney U-test). To
evaluate associations of MTX intolerance with clinically
relevant covariates - disease activity score (DAS)-28, phys-
ician global assessment (PGA), age, MTX dose, MTX
route and non-steroidal anti-inflammatory drug (NSAID)
use - multivariate logistic regression was performed. Stat-




Of 296 patients, 5 were excluded due to diagnosis other
than RA or PsA (n = 3 with ankylosing spondylitis; n = 1
with peripheral spondyloarthritis; and n = 1 with sclero-
derma). Table 1 shows the baseline characteristics of 291patients; the majority was female (62.2%), 249 (85.6%)
had RA and 42 (14.4%) had PsA with low to moderate
DAS-28.MTX intolerance prevalence in RA and PsA
One hundred and twenty-three (42.3%) RA and PsA
patients experienced at least one gastrointestinal
symptom during MTX treatment. The most prevalent
gastrointestinal symptom after MTX administration
was nausea, affecting 93 (32.0%) patients, whereas ab-
dominal pain occurred in 11.3% and vomiting in 6.5%
(Table 2). Pre-treatment nausea was the most preva-
lent; 8.6% had anticipatory and 11.0% associative nau-
sea. Anticipatory vomiting was the least prevalent,
affecting 1.7% (Table 2). Behavioural symptoms, over-
all, affected 16.5% of patients, with restlessness being
the most prominent symptom in 13.1% of patients
(Table 2).
Table 2 Prevalence of MTX-related gastrointestinal symptoms in all patients and in intolerant patients by route of
MTX administration
All patients Tolerant to MTX Intolerant to MTX Oral MTX Parenteral MTX
Total 291 (100) 259 (89.0) 32 (11.0) 194 (66.7) 97 (33.3)
Cutoff score ≥6 32 (11.0) 0 (0) 32 (100) 12 (6.2) 20 (20.6)a
Abdominal pain 44 (15.1) 24 (9.3) 20 (62.5) 7 (58.3) 13 (65.0)
After MTX 33 (11.3) 18 (6.9) 15 (46.9) 5 (41.7) 10 (50.0)
Anticipatory 17 (5.8) 5 (1.9) 12 (37.5) 5 (41.7) 7 (35.0)
Associative 17 (5.8) 6 (2.3) 11 (34.4) 4 (33.3) 7 (35.0)
Nausea 100 (34.4) 68 (26.3) 32 (100) 12 (100) 20 (100)
After MTX 93 (32.0) 61 (23.6) 32 (100) 12 (100) 20 (100)
Anticipatory 25 (8.6) 7 (2.7) 18 (56.3) 6 (50.0) 12 (60.0)
Associative 32 (11.0) 15 (5.8) 17 (53.1) 5 (41.7) 12 (60.0)
Vomiting 22 (7.6) 11 (4.2) 11 (34.4) 5 (41.7) 6 (30.0)
After MTX 19 (6.5) 9 (3.5) 10 (31.3) 5 (41.7) 5 (25.0)
Anticipatory 5 (1.7) 0 (0) 5 (15.6) 2 (16.7) 3 (15.0)
Behavioural symptoms 48 (16.5) 22 (8.5) 26 (81.3) 7 (58.3) 19 (95.0)b
Restlessness 38 (13.1) 16 (6.2) 22 (68.8) 6 (50.0) 16 (80)
Irritability 29 (10.0) 7 (2.7) 22 (68.8) 5 (41.7) 17 (85.0)c
Refusal of MTX 13 (4.5) 1 (0.4) 12 (37.5) 2 (16.7) 10 (50.0)
Values are number (%) of patients. All domains and individual items differentiate between tolerant and intolerant patients (P < 0.001). aP < 0.001 versus oral MTX,
by chi-square test; bP = 0.02 versus oral MTX, by chi-square test, cP = 0.02 versus oral MTX, by chi-square test. MTX, methotrexate.
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having a median score of 9 (IQR: 6.25 to 12.00). The
prevalence and severity of MTX intolerance was similar
in RA (n = 26 (10.4%), score 9 (6.8 to 12.3)) and PsA
(n = 6 (14.3%), score 7 (6.0 to 13.0)). All intolerant
patients (100%) experienced post-treatment nausea,
whereas 46.9% had post-treatment abdominal pain and
31.3% had post-treatment vomiting (Table 2). The most
prevalent pre-treatment gastrointestinal symptoms were
anticipatory and associative nausea, affecting 56.3% and
53.1% of intolerant patients respectively, followed by
anticipatory abdominal pain in 37.5% and associative
abdominal pain in 34.4%. Anticipatory vomiting oc-
curred in 15.6% of intolerant patients, whereas this
symptom did not occur in tolerant patients. Overall, be-
havioural symptoms occurred in 81.3% of intolerant pa-
tients, of whom 37.5% refused MTX.
MTX-intolerant patients were younger than the MTX-
tolerant (mean age 51.6 +/− 12.2 versus 60.4 +/− 12.1
years, P < 0.001). MTX dose, DAS-28, PGA, erythrocyte
sedimentation rate (ESR), co-medication use, history of
peptic ulcers (3.8% of all patients) and smoking (25.8% of
all patients) did not differ between the two groups. Gender
distribution did not differ between MTX-intolerant and
MTX-tolerant patients (female, 75.0% versus 60.6%; male,
25.0% versus 39.4%), but more female (75%) than male
patients (25%) were intolerant, although this was not statis-
tically significant.MTX intolerance prevalence in patients on oral and
parenteral MTX
MTX intolerance prevalence was significantly higher in
patients on parenteral (20 of 97, 20.6%) than on oral MTX
(12 of 194 m 6.2%, P < 0.001) (Table 2). Significantly more
patients on parenteral than on oral MTX exhibited behav-
ioural symptoms (P = 0.02), whereas other symptoms were
comparable between the two groups. The median MTX
intolerance score was higher in intolerant patients on par-
enteral than on oral MTX, although not significantly (9.5,
IQR 7.0 to 15.5) versus 7.5, IQR 6.0 to 9.0), P = 0.08).
Patients on parenteral MTX received the same MTX dose
(20.0 mg/week, IQR 15.0 to 25.0) as patients on oral MTX
(20.0 mg/week, IQR 15.0 to 20.0).
In the multivariate analysis, older patients were less
likely to have MTX intolerance (odds ratio (OR) 0.93, 95%
m, CI 0.89, 0.97; P = 0.001). If age was stratified into two
groups, namely ≥65 and <65 years, older patients were
again less likely to have MTX intolerance (OR 0.21, 95%
CI 0.06, 0.85; P = 0.03) whereas patients with higher PGA
(OR 1.26, 95% CI 1.05, 1.51; P = 0.01) and those receiving
parenteral MTX (OR 3.88, 95% CI 1.41, 10.62; P = 0.01)
were more likely to have MTX intolerance.
Discussion
We showed that besides the well-known MTX-induced
gastrointestinal symptoms upon MTX administration, RA
and PsA patients also had anticipatory and associative
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administration, collectively termed MTX intolerance. MTX
intolerance prevalence in RA and PsA patients was 11%.
Studies in RA have found similar occurrence rates com-
pared to our study [7,11]; nausea was the most prevalent
symptom, occurring in 14.4 to 28.0% compared to 32.0% in
our cohort, followed by abdominal pain in 9.7 to 10.6%
compared to 11.3% in our cohort and vomiting in 3.4%
compared to 6.5% in our cohort. Of note is that compari-
sons were made between symptoms occurring only after
MTX, as it is likely that previous studies took solely these
symptoms into account (not the pre-treatment symptoms).
In contrast to JIA in which the prevalence of MTX in-
tolerance reached 50.5%, the prevalence in RA/PsA was
considerably lower at 11%. MTX intolerance severity was
lower in adults (score 9) than in children (score 12) (P =
0.003). Substantially lower MTX intolerance prevalence in
RA/PsA was due to: a) lower percentage of adults with
score ≥6, and b) lower percentage of adults (24.4% versus
67% in JIA) with at least one anticipatory, associative and/
or behavioural symptoms. As anticipatory and associative
symptoms arise as classic conditioning responses to phys-
ical symptoms upon MTX use, the lower percentage of
RA/PsA patients with pre-treatment symptoms suggests a
weaker, classic, conditioning response in adults than in
children taking MTX. This is supported by the fact that,
whereas 82% of 204 JIA patients with symptoms after
MTX also had symptoms before MTX intake, only 51% of
106 RA/PsA patients with symptoms after MTX had
symptoms before MTX intake.
MTX intolerance prevalence was higher in patients on
parenteral (20.8%) than on oral MTX (6.2%), which we
also demonstrated for JIA [13,14]. This difference was
caused by more behavioural symptoms in the parenteral
group. Aversion towards needles, besides aversion towards
MTX, could have contributed to a higher prevalence of
these symptoms. It is common to switch patients from
oral to parenteral MTX due to gastrointestinal symptoms
[5]. Indeed, 13 of 20 intolerant patients on parental MTX
had been switched to this route from oral MTX due to
gastrointestinal symptoms. Considering their past symp-
toms on oral MTX, the patients who switched may have
been more prone to develop gastrointestinal and behav-
ioural symptoms on parenteral MTX, resulting in higher
MTX intolerance prevalence in the parenteral group.
Besides the observed association between parenteral
MTX and MTX intolerance, age was also associated with
MTX intolerance, namely older patients (>65 years) were
less likely to have MTX intolerance than younger patients
(≤65 years). In previous studies, neither younger nor older
age (>65 years) was associated with occurrence of MTX-
related gastrointestinal and other side effects [15,16]. Val-
idation studies are required to determine whether younger
age is a risk factor for MTX intolerance.Anticipatory and associative gastrointestinal symptoms
could have a negative impact on patients’ quality of life
[14] and impede the use of MTX. Nevertheless, these
symptoms are clinically not very evident [13]. Conse-
quently, they cannot be easily detected by physician as-
sessment only, but can be detected using the MISS [13].
Therefore, using the MISS is advantageous as it allows
early detection of symptoms. This could create a window
of opportunity for timely treatment of MTX intolerance,
as well as for early treatment of emerging physical symp-
toms, which could prevent the development of condi-
tioned responses and therefore MTX intolerance. Similar
to JIA, treatment of (physical) symptoms could include
lowering the MTX dose [17], switching to parenteral
MTX [14,18,19] or starting behavioural therapy [20] or
anti-emetics [19].
Although the MISS was validated and employed to
measure MTX intolerance prevalence in JIA, it provided a
structured platform to assess the type of MTX-induced
gastrointestinal symptoms in RA/PsA. Nevertheless, the
MISS should be validated in adults with rheumatic dis-
eases. Furthermore, this study does not reveal variables as-
sociated with MTX intolerance development, nor does it
demonstrate the frequency of MTX discontinuation or of
switching to other medication due to MTX intolerance.
Prospective trials are required to address these issues.
This is the first study to demonstrate using a standard-
ized questionnaire, that MTX intolerance occurs in 11%,
more frequently in patients on parenteral than on oral
MTX, and possibly persists after a switch from oral to par-
enteral MTX. Since persistent gastrointestinal symptoms
are the major reason to discontinue MTX, intolerant pa-
tients could be more prone to stop MTX or switch to (less
effective) DMARDs or expensive biological agents [12].
Upon validation in adults, the MISS may be used in daily
clinical practice to closely monitor patients and to inter-
vene timely using the abovementioned approaches in
order to prevent or reduce the negative impact of MTX
intolerance on patients’ daily lives, compliance and con-
tinuation of an effective treatment.
Conclusions
Using a standardized MISS questionnaire, we showed
that besides the well-known MTX-induced gastrointes-
tinal symptoms upon MTX administration, RA and PsA
patients also experienced anticipatory and associative
gastrointestinal and behavioural symptoms before MTX
administration, which develop as a classical conditioning
response to physical symptoms after MTX. The preva-
lence of MTX intolerance was 11%. MTX intolerance
occurred more often in patients on parenteral (20.6%)
than in those on oral MTX (6.2%) and persisted after a
switch from oral to parenteral MTX. As persisting MTX
intolerance could have a negative impact on patients’
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patients on MTX should be monitored with the MISS
for early detection of MTX intolerance. This would cre-
ate a window of opportunity to intervene timely and
avoid incompliance and discontinuation of an otherwise
efficacious treatment.
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